Monalizumab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 16 clinical trials, of which 4 were completed, 7 are ongoing, 2 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Monalizumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Monalizumab is expected to reach an annual total of $22 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Monalizumab (NN-8765, IPH-2201) is under development for the treatment of HER2-positive breast cancer, solid cancers including non-small cell lung cancer and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through intravenous and subcutaneous route. It is a first-in-class humanized IgG4 antibody that targets killer cell lectin-like receptor subfamily C member 1 (KLRC1, NKG2A). It was under development for the treatment of squamous cell carcinoma of the oral cavity, gastro-esophageal junction carcinoma and rheumatoid arthritis, high grade ovarian cancer, endometrial cancer, fallopian tube cancer, cervical cancer, esophageal and peritoneal cancer, hematological cancers like relapsed/refractory chronic lymphocytic leukemia (CLL), recurrent squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, or larynx) colorectal cancer.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$44,351 million for the fiscal year ended December 2022 (FY2022), an increase of 18.5% over FY2021. The operating profit of the company was US$3,757 million in FY2022, compared to an operating profit of US$1,056 million in FY2021. The net profit of the company was US$3,288 million in FY2022, compared to a net profit of US$112 million in FY2021.
For a complete picture of Monalizumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.